Clinical background
1) EPA and DHA contribute to the normal function of the heart - EU aproved health claim
EFSA journals: 2010;8(10):1796, 2011;9(4):2078
2) Docosahexaenoic acid (DHA) maternal intake contributes to the normal brain development of the foetus and breastfed infants - EU aproved health claim
EFSA journal: Q-2008-773
3) Docosahexaenoic acid (DHA) maternal intake contributes to the normal development of the eye of the foetus and breastfed infants - EU aproved health claim
EFSA journal: Q-2008-675
4) DHA contributes to maintenance of normal brain function - EU aproved health claim
EFSA journals: 2010;8(10):1734, 2011;9(4):2078
5) DHA contributes to the maintenance of normal vision - EU aproved health claim
EFSA journals: 2010;8(10):1734, 2011;9(4):2078
6) DHA contributes to the maintenance of normal blood triglyceride levels - EU aproved health claims
EFSA journal: 2010;8(10):1734
7) DHA and EPA contribute to the maintenance of normal blood pressure - EU aproved health claims
EFSA journals: 2009; 7(9); 1263, 2010;8(10):1796
8) DHA and EPA contribute to the maintenance of normal blood triglyceride levels - EU aproved health claims
EFSA journanls: 2009; 7(9); 1263, 2010;8(10):1796
Safety assesment
The Alto Omega 3 Max is a pure fish oil with controlled content of active ingredients DHA and EPA.
The product is produced in GMP licenced manufacturing plant according to EU regulation. The production is in compliance with PIC/S standards.
Whole batch production and laboratory control is done in one manufacturing place.
Alto Omega 3 Max is approved and registered by MOH.